Past event: 4th Due Diligence Summit for Life Sciences

Benchmark your due diligence practices for evaluating business development opportunities, strategic partnerships and external sources of innovation

The 4th Due Diligence Summit for Life Sciences, taking place on May 18-19, 2017 in Boston, MA, is the industry's ONLY cross-functional life science event focused on the needs of due diligence professionals. This conference will highlight the latest M&A trends in the market, educate due diligence professionals on the different aspects and challenges faced by cross-functional team members, and provide attendees with the strategies and insight they need to effectively conduct thorough due diligence to ensure a profitable investment in a new product, portfolio, company or strategic alliance.

Hot off a successful third year, this event is the perfect platform for due diligence professionals to convene with their functional counterparts to discuss the best ways to work across their organization, as well as with external advisors. Join your peers at the industry's leading event to gain valuable insight from industry leaders, and take advantage of the quality networking opportunities at this two-day event. Register today!


Top Five Reasons to Attend
  1. Create and deploy an effective gap analysis to help identify gaps in the product portfolio and regulatory standards
  2. Gain valuable insight from cross-functional due diligence team members, as well as leaders in the medical device and biotech industries
  3. Understand how to develop strategic objectives for a deal and accelerate synergies to ensure a high-performance organization
  4. Learn how to evaluate and effectively manage strategic alliances through case studies from industry leaders
  5. Evaluate the scope, validity and enforceability of a target's patents

Speakers

  • Robert Bagdorf, M.D., MBA, Vice President, Worldwide Business Development, PFIZER
  • Catherine Baillis, Vice President, Head of Business Development Operations, Business Development and Licensing, SANOFI
  • Joseph Bulvid, Former Vice President, Global Benefits, Planning and Mergers and Acquisitions, JOHNSON & JOHNSON, Adjunct Professor, Leadership and Human Capital Management Department, NYU
  • John Dougherty, Partner, HAUG PARTNERS LLP
  • Luba Greenwood, Vice President, Global Business Development and Mergers and Acquisitions, F. HOFFMANN-LA ROCHE
  • Matthew Handel, President, RECENSA THERAPEUTICS
  • Matthew Handel, Vice President, Commercial Search & Evaluation, G&W LABORATORIES
  • Diane Harvey, Ph.D., Senior Director, Search and Evaluation, TEVA
  • Courtney Horvath, Ph.D., DABT, Preclinical Safety Global Coordinator, Novartis Institutes for Biomedical Research, NOVARTIS
  • Michael B. Kennedy II, Vice President - DataSite, MERRILL CORPORATION
  • Curt H. LaBelle, M.D., MBA, President, GLOBAL HEALTH INVESTMENT FUND
  • Lizabeth Leveille, Executive Director, BD&L Transactions, MERCK
  • Edward Mahony, Executive Vice President, Due Diligence and Integration, PURDUE PHARMA
  • Mike Myers, Senior Director, Lilly Research Labs - Due Diligence, ELI LILLY
  • Marc Schwabish, US Head, Pharmaceutical Business Development & Licensing, BAYER
  • David Shoultz, Ph.D., M.S., MBA, Global Program Leader, Drug Development, PATH
  • Allan Weber, CEO, ESSENTIAL PHARMACEUTICAL

Please fill in your name and email to receive the conference agenda of this event.


Conference Day One - Thursday, May 18, 2017
  • Including: Morning & Afternoon Networking Break, Luncheon
Conference Day Two - Friday, May 19, 2017
  • Including: Morning Networking Break, Luncheon

The agenda is available as PDF under downloads at the right side of the page.

Venue

The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.

Who Should Attend

This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas:
  • Due Diligence
  • Business Development
  • Strategic Alliance/Alliance Management
  • Mergers and Acquisitions
  • Licensing
  • Intellectual Property and Patent Counsel
  • Search and Evaluation
  • Portfolio Management
  • Scientific Assessment
  • General Counsel/Corporate Counsel
  • Legal and Regulatory Compliance
  • Regulatory Affairs
  • Clinical Medicine
  • Research and Development
  • Clinical Operations
  • Life Cycle Management

This conference is also of interest to:
  • Investment Banks
  • Private Equity Firms
  • Venture Capitalists
  • Data Room Providers
  • Due Diligence Consultants
  • Law Firms
  • Clinical Affairs and CRO Partners
  • Regulatory Affairs and Compliance Partners


Venue

Hyatt Regency Boston
1 Avenue De Lafayette
Boston, MA 02111

Located in the heart of downtown, our Boston hotel is the ideal destination for business and leisure travelers alike. From food that feeds the mind and body and inspiring spaces for conversation to our contemporary guest rooms that morph between office and oasis, Hyatt Regency Boston will enhance your travel experience. For exciting area activities, tour the Freedom Trail, visit the Museum of Fine Arts or catch a game at historic Fenway Park, all just minutes away.

To make reservations please call 888-421-1442 or 617-912-1234 and request the negotiated rate for ExL’s 4th Due Diligence Summit. To make reservations online, click here

The group rate is available until April 26, 2017. Please book your room early as rooms available at this rate are limited.
Event details
Organizer : ExL
Event type : Conference
Reference : ASDE-15923